The Shifting Landscape of AI & GenAI Adoption in Pharma
The pharmaceutical industry is navigating a shifting landscape as artificial intelligence (AI) and generative AI (GenAI) move from experimental pilots to enterprise-wide adoption. While the potential to accelerate R&D, optimize clinical trials and improve decision-making is immense, realizing measurable impact requires more than new technology. Success hinges on strategy, governance, culture and talent.
This white paper explores how pharma leaders can turn GenAI promise into scalable value. It highlights emerging adoption models, the tension between internal build and external partnerships and the enablers of sustainable maturity. Readers will gain actionable insights into aligning AI with enterprise priorities and overcoming common barriers to scale.
What’s Inside:
- Key themes shaping AI & GenAI adoption across pharma
- Horizontal vs. vertical adoption models and trade-offs
- Data governance challenges and FAIR principles
- Internal vs. external sourcing strategies for GenAI
- Outcome-driven adoption models anchored in measurable value
- Five strategic pathways to enterprise-scale AI maturity
Download the white paper to learn more!
